Preventive Cardiology: Finding Cardiovascular Risk Before Symptoms Appear

This guide is part of the HormoneSynergy® Longevity Medicine Education Series, our clinical library covering cardiovascular prevention, metabolic health, body composition, hormones, cognitive longevity and healthy aging.

Under the leadership of Dr. Kathryn Retzler, HormoneSynergy® has spent more than 25 years working at the intersection of preventive medicine, metabolic health and hormone care. Our preventive cardiology work follows the same basic approach: measure what matters, determine whether disease is already present, and treat meaningful risk rather than waiting for symptoms.

Cardiovascular prevention has changed considerably over the past several years. A standard cholesterol panel still matters, but it is no longer the entire conversation. ApoB can help identify atherogenic particle burden. Lipoprotein(a), or Lp(a), can reveal inherited risk that otherwise remains hidden. Blood pressure guidelines have become more aggressive. The American Heart Association's PREVENT™ equations now incorporate cardiovascular, kidney and metabolic health into contemporary risk estimation.

Imaging has also become more useful. Coronary artery calcium scoring can identify calcified coronary plaque. Carotid ultrasound can show vascular disease outside the coronary arteries. Coronary CT angiography can directly visualize both calcified and noncalcified coronary plaque when that level of information is clinically appropriate.

The objective is not more testing. It is better information.

What Preventive Cardiology Actually Means

Traditional medicine often encounters coronary disease after something has happened. A patient develops chest pain. A stress test becomes abnormal. An emergency department evaluates shortness of breath. A heart attack exposes disease that had been developing silently for years.

Preventive cardiology tries to move the timeline earlier.

That begins with conventional information: age, blood pressure, smoking, diabetes, kidney function, cholesterol, medications and family history. Those factors remain important because decades of outcome data show that they matter.

The next question is whether conventional assessment is telling the whole story.

A person can have a relatively ordinary LDL-C and a high ApoB. Another can have excellent metabolic health but markedly elevated inherited Lp(a). Someone with only moderate laboratory abnormalities may already have coronary plaque. Another person with several risk factors may still have no detectable coronary calcium.

The purpose of better testing is to resolve those uncertainties when doing so will change what we recommend.

The PREVENT™ Era of Cardiovascular Risk Assessment

The older Pooled Cohort Equations have now been replaced in current U.S. lipid guidance by the American Heart Association's PREVENT-ASCVD equations for appropriate primary-prevention patients.

PREVENT stands for Predicting Risk of Cardiovascular Disease EVENTs. It was developed using data from more than 6.5 million U.S. adults and incorporates cardiovascular, kidney and metabolic health rather than treating them as unrelated systems.

For adults without known cardiovascular disease, PREVENT can estimate both shorter-term and longer-term cardiovascular risk. The 2026 dyslipidemia guideline uses 10-year PREVENT-ASCVD categories of:

• Low risk: less than 3%
• Borderline risk: 3% to less than 5%
• Intermediate risk: 5% to less than 10%
• High risk: 10% or greater

Risk calculators are useful. They are not diagnoses.

A calculator estimates the probability of an event in a population of people who resemble the patient. It cannot tell us whether that particular person already has coronary plaque. That is where additional biomarkers, family history and selective imaging may refine the discussion.

The Cardiovascular Markers We Pay Attention To

No laboratory panel can summarize cardiovascular risk in one number.

Depending on the individual, useful measurements may include LDL-C, non-HDL cholesterol, ApoB, triglycerides, Lp(a), glucose and HbA1c, fasting insulin, kidney function and hs-CRP. Blood pressure belongs in the same discussion even though it is not a blood test.

Family history can change the interpretation considerably. So can smoking, chronic kidney disease, inflammatory disease, menopause history and established diabetes.

The 2026 dyslipidemia guideline also recognizes several risk enhancers that can matter when conventional risk appears borderline. These include elevated Lp(a), persistent triglyceride elevation, hs-CRP of at least 2 mg/L on more than one occasion, chronic inflammatory disease, cardiovascular-kidney-metabolic syndrome and selected reproductive risk factors.

Those markers are not interchangeable. Each tells us something different.

Why ApoB Has Become So Important

Atherosclerosis begins when ApoB-containing lipoprotein particles cross into the arterial wall and become retained there.

LDL-C measures the amount of cholesterol contained inside LDL particles. ApoB more closely reflects the number of atherogenic particles in circulation because each major atherogenic particle carries one ApoB molecule.

Most of the time LDL-C and ApoB move in roughly the same direction. Sometimes they do not.

Discordance is particularly relevant when triglycerides are elevated, insulin resistance or diabetes is present, or LDL-C has already been lowered substantially. In those settings, someone may carry more atherogenic particles than LDL-C alone suggests.

The 2026 guideline specifically notes that ApoB can help identify residual lipoprotein-related risk after LDL-C and non-HDL cholesterol goals have been reached.

Read our full guide: ApoB Explained: The Most Important Cholesterol Marker.

For the common question of how ApoB differs from LDL-C, see LDL vs ApoB: Which Better Predicts Cardiovascular Risk?.

Why Everyone Should Know Their Lp(a)

Lipoprotein(a) is different from most cardiovascular risk markers because its concentration is largely inherited.

Someone can exercise regularly, eat carefully, maintain a healthy weight and still have a markedly elevated Lp(a).

The 2026 ACC/AHA guideline recommends that Lp(a) be measured at least once in adulthood. A concentration of 125 nmol/L or 50 mg/dL or greater is considered a cardiovascular risk-enhancing level. Very high levels carry still greater risk.

Lifestyle changes generally have little effect on Lp(a) itself. That does not make the result useless. It means the rest of cardiovascular risk becomes more important to manage well, particularly ApoB/LDL exposure, blood pressure, smoking and metabolic health.

Lp(a) also complicates the assumption that a favorable conventional cholesterol panel means cardiovascular risk must be low.

Read more: Lp(a): The Inherited Heart Risk Most People Have Never Measured.

Where hs-CRP Fits

High-sensitivity C-reactive protein, or hs-CRP, gives us information about systemic inflammatory activity.

It is not a coronary plaque test and it is not specific to cardiovascular disease. Infection, visceral adiposity, smoking, periodontal disease, autoimmune conditions and many other processes can raise it.

Current lipid guidance recognizes hs-CRP of at least 2 mg/L on repeated measurements as a cardiovascular risk enhancer in the appropriate setting. The repeat measurement matters because a single elevated result obtained during an infection or inflammatory flare may tell us very little about baseline cardiovascular risk.

hs-CRP also does not replace ApoB. One describes inflammatory risk. The other describes atherogenic lipoprotein burden.

Our deeper review is here: Inflammation and Atherosclerosis: ApoB, hs-CRP and Plaque.

Blood Pressure Still Matters Enormously

Advanced testing gets attention because it is new. Blood pressure remains one of the most powerful modifiable cardiovascular risk factors we have.

The 2025 ACC/AHA hypertension guideline defines stage 1 hypertension as 130–139 mm Hg systolic or 80–89 mm Hg diastolic and uses an overarching treatment goal below 130/80 mm Hg for most adults with hypertension.

The same guideline now uses PREVENT cardiovascular risk to help determine when medication should be started in people with stage 1 hypertension.

Accurate measurement matters. Office readings can be misleading in either direction. Home blood-pressure monitoring can help establish whether elevated readings are persistent and can show whether treatment is actually working outside the clinic.

There is nothing technologically glamorous about treating hypertension. There is a tremendous amount of outcome evidence behind doing it well.

Metabolic Health, Kidney Health and Cardiovascular Risk

Cardiology, endocrinology and metabolic medicine are increasingly converging for a reason.

The American Heart Association now uses the term cardiovascular-kidney-metabolic syndrome, or CKM syndrome, to describe the interconnected relationship among obesity, diabetes, kidney disease and cardiovascular disease.

The 2026 CKM guideline formally incorporates PREVENT risk estimation and CKM staging into cardiovascular prevention.

Clinically, this overlap is familiar. Visceral adiposity often travels with insulin resistance, higher blood pressure, elevated triglycerides, fatty liver and sleep apnea. Kidney dysfunction independently changes cardiovascular risk. Diabetes accelerates vascular disease through several pathways at once.

This is why a preventive heart evaluation may include measurements that do not look like traditional cardiology: glucose, HbA1c, fasting insulin, kidney function and body composition.

For a deeper discussion, see our Metabolic Health & Insulin Resistance Guide.

Visceral Fat Is Different From Body Weight

Scale weight is a poor description of metabolic health.

Two people at the same weight can have very different amounts of visceral fat and skeletal muscle. Those differences influence insulin sensitivity, glucose disposal, blood pressure and cardiometabolic health.

DEXA body composition testing can estimate visceral adipose tissue while also measuring total fat and lean mass. It does not diagnose coronary artery disease, but it provides useful information about part of the metabolic environment in which cardiovascular disease develops.

At HormoneSynergy®, DEXA and SECA body composition data may be used alongside cardiovascular testing rather than treated as cosmetic measurements.

Learn more about DEXA body composition and visceral fat testing in Portland and Lake Oswego.

Risk Markers and Plaque Imaging Answer Different Questions

This is one of the most important distinctions in preventive cardiology.

ApoB, Lp(a), blood pressure, smoking, glucose regulation and hs-CRP help us estimate the probability that cardiovascular disease may develop or progress.

Imaging asks a different question:

Is atherosclerosis already visible?

Those questions overlap, but they are not identical.

A patient may have elevated risk factors and no currently detectable calcified coronary plaque. Another may have moderate-looking laboratory values and surprisingly extensive plaque. Once structural disease has been identified, the conversation usually becomes more concrete.

Coronary Artery Calcium: A Proven Risk-Reclassification Tool

A coronary artery calcium scan is a noncontrast CT that measures calcified plaque in the coronary arteries.

Its strength is not that it shows all coronary disease. It does not. Its strength is the enormous amount of outcome data linking coronary calcium burden with future cardiovascular risk.

The 2026 ACC/AHA dyslipidemia guideline recommends selective use of CAC to help reclassify risk, particularly when the decision to start or intensify lipid-lowering treatment remains uncertain. Current guidance specifically discusses its use in men beginning around age 40 and women around age 45 when risk assessment would benefit from additional information.

A calcium score of zero can be reassuring in the appropriate clinical context. It does not mean lifetime risk is zero, and it does not exclude noncalcified plaque.

That last point becomes increasingly relevant in younger patients and in people with specific inherited or metabolic risk.

Read our full guide: Coronary Artery Calcium Score Explained.

CCTA and Cleerly®: Looking Beyond Calcium

Coronary CT angiography, or CCTA, answers a more detailed anatomic question.

Unlike a calcium score, CCTA uses intravenous contrast to visualize the coronary arteries themselves. It can identify both calcified and noncalcified plaque, demonstrate coronary narrowing and provide information about total plaque burden and composition.

Research published in 2025 found that several CCTA-derived measures of plaque burden were associated with subsequent major cardiovascular events, including total plaque volume and low-attenuation plaque burden.

Cleerly® is an AI-assisted analytic platform applied to appropriate CCTA images. The analysis can quantify plaque burden, plaque composition, distribution and stenosis.

That does not make CCTA the right screening test for everyone.

As of 2026, CCTA is established clinically for several diagnostic uses, particularly the evaluation of coronary disease in symptomatic patients. Its role as broad population screening in asymptomatic adults remains an evolving area. Recent reviews emphasize that although CCTA can refine plaque assessment, randomized trials have not yet demonstrated that universal CCTA screening improves cardiovascular outcomes compared with current prevention strategies.

Age, symptoms, renal function, contrast allergy, prior imaging, radiation exposure, family history, inherited risk and whether the result would change management all belong in the decision.

For patients in whom a detailed coronary plaque assessment is appropriate, see our Preventive Cardiology & Coronary Plaque Assessment guide.

Carotid Ultrasound and CIMT

The carotid arteries provide another opportunity to look directly for vascular disease without radiation or intravenous contrast.

Carotid ultrasound can identify focal carotid plaque and can measure carotid intima-media thickness, or CIMT. These are related measurements, but they should not be treated as identical.

The presence of actual carotid plaque is stronger evidence of atherosclerotic disease than a small difference in intima-media thickness alone. Contemporary cardiovascular guidelines place more emphasis on demonstrated plaque than on using CIMT as a universal screening measurement for every adult.

At HormoneSynergy®, VasoLabs® carotid ultrasound may include both plaque assessment and CIMT measurement. We use that information as part of a broader cardiovascular evaluation rather than treating one arterial-wall measurement as a diagnosis.

Learn more: CIMT Ultrasound and Early Arterial Plaque Detection.

Women, Menopause and Cardiovascular Prevention

Cardiovascular prevention in women deserves more attention during the menopause transition.

Blood pressure, LDL-C, body composition, insulin sensitivity and glucose regulation can all shift during midlife. Premature menopause is also recognized in contemporary lipid guidance as a cardiovascular risk enhancer.

This does not mean menopause itself is cardiovascular disease. It means midlife provides an unusually useful opportunity to reassess the risk profile rather than waiting until a woman reaches the age at which conventional risk scores begin to look concerning.

Hormone therapy should be considered in its own clinical context and is not a substitute for blood-pressure management, lipid treatment or plaque assessment when those are indicated.

Prevention Includes Medical Treatment

There is a tendency in parts of longevity medicine to present lifestyle care and prescription medicine as opposites. Cardiovascular outcomes do not support that distinction.

Exercise, nutrition, smoking cessation, adequate sleep and improving body composition matter enormously. So do medications when the indication is there.

Statins remain first-line lipid-lowering therapy for many patients because randomized cardiovascular outcome data are extensive. Ezetimibe, PCSK9-targeting therapies, bempedoic acid and other treatments may be considered when additional lipid lowering is necessary or statin therapy alone is insufficient or poorly tolerated.

Hypertension deserves treatment. Diabetes deserves treatment. Smoking deserves aggressive intervention. Sleep apnea deserves evaluation and management.

Preventive medicine is not defined by avoiding prescriptions. It is defined by using effective treatment before avoidable disease produces an irreversible event.

The Lifestyle Foundation Has Not Changed

Even as cardiovascular testing becomes more sophisticated, the fundamental behaviors remain remarkably durable.

The American Heart Association's Life's Essential 8 includes nutrition, physical activity, tobacco avoidance, sleep, weight, cholesterol, blood glucose and blood pressure.

For most adults, that means regular aerobic activity, resistance training, a largely Mediterranean-style dietary pattern, adequate sleep, avoidance of smoking and maintenance of metabolic health.

These habits do not guarantee that someone will avoid cardiovascular disease. Genetics matter. Lp(a) matters. Age matters. Established plaque matters.

They do, however, influence several major cardiovascular pathways at the same time and remain the foundation on which medical treatment is added.

The HormoneSynergy® Approach to Preventive Cardiology

Our interest is not in producing the longest laboratory report.

We want to know whether risk is being missed.

That can mean looking beyond LDL-C to ApoB. It can mean checking Lp(a) once rather than discovering an inherited risk after an event. It can mean recognizing that blood pressure is consistently 138/84 rather than calling it "a little high." It can mean identifying increasing visceral fat and fasting insulin before diabetes develops.

And when the clinical question requires it, it can mean looking directly for vascular or coronary plaque.

At HormoneSynergy®, cardiovascular assessment may include advanced laboratory testing, VasoLabs® carotid ultrasound, DEXA and SECA body composition analysis, and selective use of coronary imaging such as CAC or CCTA with Cleerly® analysis.

Not every patient needs every test.

The physician's job is to decide which information is likely to change prevention and then act on what the information shows.

Our broader clinical approach is described in Preventive Cardiology & Coronary Plaque Assessment at HormoneSynergy®.

The Bottom Line

Cardiovascular disease often develops long before it announces itself.

Modern preventive cardiology gives us several ways to move that discovery earlier. PREVENT™ estimates overall risk. ApoB helps quantify atherogenic particle burden. Lp(a) can uncover inherited risk. hs-CRP provides information about systemic inflammatory risk. Blood pressure, kidney function and metabolic health add important context.

Imaging answers the question laboratory testing cannot: whether atherosclerosis is already visible.

The result is not a search for perfect numbers. It is a clearer understanding of where risk is coming from, whether disease is already present, and how aggressively prevention should proceed.

Preventive Cardiology Guides

For deeper coverage of individual cardiovascular tests and biomarkers:

• ApoB Explained: The Most Important Cholesterol Marker
• LDL vs ApoB: Which Better Predicts Heart Disease?
• Lp(a): The Inherited Heart Risk Most People Have Never Measured
• Inflammation and Atherosclerosis: ApoB, hs-CRP and Plaque
• Coronary Artery Calcium Score Explained
• CIMT Ultrasound and Early Arterial Plaque Detection
• Preventive Cardiology & Cleerly® Coronary Plaque Assessment

Frequently Asked Questions

What is preventive cardiology?

Preventive cardiology focuses on identifying and treating cardiovascular risk before a heart attack, stroke or other cardiovascular event occurs. It can include conventional risk assessment, advanced biomarkers, lifestyle treatment, prescription therapy and selective imaging for subclinical atherosclerosis.

What is the PREVENT cardiovascular risk calculator?

PREVENT™ is the American Heart Association's contemporary cardiovascular risk model. It incorporates cardiovascular, kidney and metabolic factors and can estimate 10-year and longer-term cardiovascular risk in appropriate adults without known cardiovascular disease.

Should everyone have ApoB tested?

ApoB is particularly useful when triglycerides are elevated, diabetes or metabolic dysfunction is present, LDL-C is already low, or conventional cholesterol measurements may underestimate atherogenic particle burden. Current guidelines give ApoB an increasing role in cardiovascular risk refinement.

How often should Lp(a) be tested?

The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. Because Lp(a) is largely genetically determined, repeated testing is usually unnecessary unless the clinical situation warrants it.

What is considered elevated Lp(a)?

Current U.S. guidance considers Lp(a) of at least 125 nmol/L or 50 mg/dL a cardiovascular risk-enhancing level. Risk rises further at substantially higher concentrations.

What does hs-CRP tell you about heart disease?

hs-CRP measures systemic inflammatory activity. A repeatedly elevated hs-CRP can add cardiovascular risk information, but it does not diagnose coronary plaque and cannot identify where inflammation is coming from.

What blood pressure is considered optimal for cardiovascular prevention?

The 2025 ACC/AHA hypertension guideline uses a treatment goal below 130/80 mm Hg for most adults with hypertension. Individual treatment decisions still depend on age, medical conditions, medication tolerance and overall cardiovascular risk.

What is the difference between a calcium score and CCTA?

A coronary calcium score is a noncontrast CT that measures calcified coronary plaque. CCTA uses intravenous contrast and can visualize both calcified and noncalcified plaque, coronary narrowing and other anatomic features of coronary atherosclerosis.

Is a calcium score of zero the same as having no coronary plaque?

No. A calcium score of zero means no calcified coronary plaque was detected. Noncalcified plaque can still be present, particularly in younger patients and some people with significant inherited or metabolic risk.

Should every healthy adult have a CCTA?

No. CCTA can provide detailed coronary plaque information, but it is not currently recommended as universal screening for all asymptomatic adults. The decision should be based on risk, age, symptoms, prior testing, kidney function, contrast considerations and whether the result is likely to change treatment.

What does Cleerly® add to CCTA?

Cleerly® uses AI-assisted analysis of suitable CCTA images to quantify coronary plaque burden, plaque composition, distribution and stenosis. It does not replace the CT scan itself and is not automatically appropriate for every patient.

Can carotid ultrasound detect atherosclerosis?

Yes. Carotid ultrasound can identify carotid plaque and evaluate arterial-wall characteristics. The presence of focal carotid plaque provides evidence of vascular atherosclerosis. CIMT measurement may add context but should not be treated as a stand-alone diagnosis of cardiovascular disease.

Can lifestyle changes replace statins or blood-pressure medication?

Sometimes lifestyle improvement is sufficient for lower-risk patients, but not always. When cardiovascular risk or established disease warrants medication, prescription therapy and healthy lifestyle behaviors are complementary rather than competing strategies.

Research & Guidelines

1. American College of Cardiology/American Heart Association. 2026 Guideline on the Management of Dyslipidemia. American Heart Association
2. American Heart Association. PREVENT™ Cardiovascular Risk Equations. PREVENT™ Calculator Information
3. American Heart Association/American College of Cardiology/American Diabetes Association/American Society of Nephrology. 2026 Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. AHA CKM Guideline
4. American College of Cardiology/American Heart Association. 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. AHA Guideline Summary
5. Bell JS, et al. Plaque quantification from coronary computed tomography angiography in predicting cardiovascular events: A systematic review and meta-analysis. Journal of Cardiovascular Computed Tomography. 2025. PubMed
6. The emerging role of coronary computed tomography for prevention of cardiovascular disease in asymptomatic individuals. 2026. PubMed
7. American Heart Association. Life's Essential 8™. American Heart Association